Drugs used in the treatment of tuberculosis and leprosy

Abdelwahab, 2021, Effect of clofazimine concentration on QT prolongation in patients treated for tuberculosis, Antimicrobial Agents and Chemotherapy, 65, 10.1128/AAC.02687-20 Ardhianto, 2021, Analysis of the side effect of QTc interval prolongation in the bedaquiline regimen in drug resistant tuberculosis patients, Journal of Basic and Clinical Physiology and Pharmacology, 32, 421, 10.1515/jbcpp-2020-0415 Avaliani, 2021, Effectiveness and safety of fully oral modified shorter treatment regimen for multidrug-resistant tuberculosis in Georgia, 2019–2020, Monaldi Archives for Chest Disease = Archivio Monaldi per le malattie del torace, 91 Babar, 2021, A case series of multidrug-resistant tuberculosis in renal transplant recipients: Challenges in management from a TB endemic country, Transplant Infectious Disease: An Official Journal of the Transplantation Society, 23, 10.1111/tid.13659 Bachir, 2021, Isoniazid-monoresistant tuberculosis in France: Risk factors, treatment outcomes and adverse events, International Journal of Infectious Diseases: IJID: Official Publication of the International Society for Infectious Diseases, 107, 86, 10.1016/j.ijid.2021.03.093 Baluku, 2021, Treatment outcomes of drug resistant tuberculosis patients with multiple poor prognostic indicators in Uganda: A countrywide 5-year retrospective study, Journal of Clinical Tuberculosis and Other Mycobacterial Diseases, 23, 10.1016/j.jctube.2021.100221 Buziashvili, 2021, Incidence rate and time to serious adverse events among rifampicin resistant tuberculosis patients in Georgia treated with new and repurposed anti-tuberculosis drugs, 2016–2018, Monaldi Archives for Chest Disease = Archivio Monaldi per le malattie del torace, 91 Campbell, 2021, Safety and efficacy of rifampin or isoniazid among people with mycobacterium tuberculosis infection and living with human immunodeficiency virus or other health conditions: Post hoc analysis of 2 randomized trials, Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America, 73, e3545, 10.1093/cid/ciaa1169 Charlie, 2021, Safety and efficacy of high-dose rifampicin in the management of tuberculosis meningitis: Systematic review and meta-analysis, International Journal of Mycobacteriology, 10, 312, 10.4103/ijmy.ijmy_135_21 Chiang, 2021, Latent tuberculosis therapy outcomes in dialysis patients: A retrospective cohort, American Journal of Kidney Diseases, 77, 696, 10.1053/j.ajkd.2020.06.017 Chung, 2021, Safety of latent tuberculosis infection treatment in older patients with immune-mediated inflammatory diseases, Clinical Rheumatology Cutfield, 2021, Treatment and outcomes of multidrug-resistant tuberculosis in Auckland 1995-2018, Internal Medicine Journal Cybulski, 2021, Fatal isoniazid hepatotoxicity in the deployed environment, Military Medicine, 186, 619, 10.1093/milmed/usaa414 Das, 2021, One step forward: Successful end-of-treatment outcomes of patients with drug-resistant tuberculosis who received concomitant bedaquiline and delamanid in Mumbai, India, Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America, 73, e3496, 10.1093/cid/ciaa1577 Dayyab, 2021, Early safety and efficacy of linezolid-based combination therapy among patients with drug-resistant tuberculosis in North-western Nigeria, International Journal of Mycobacteriology, 10, 129 Devrim, 2021, Isoniazid-induced hepatotoxicity in children with latent tuberculosis infection, Minerva Pediatrics, 73, 184, 10.23736/S2724-5276.17.04338-9 Dillard, 2021, Prevalence of aminoglycoside-induced hearing loss in drug-resistant tuberculosis patients: A systematic review, The Journal of Infection, 83, 27, 10.1016/j.jinf.2021.05.010 Dodani, 2021, The efficacy of isoniazid prophylaxis in renal transplant recipients in a high tuberculosis burden country, Transplant Infectious Disease: An Official Journal of the Transplantation Society, 23, 10.1111/tid.13709 Dooley, 2021, QT effects of bedaquiline, delamanid, or both in patients with rifampicin-resistant tuberculosis: A phase 2, open-label, randomised, controlled trial, The Lancet Infectious Diseases, 21, 975, 10.1016/S1473-3099(20)30770-2 Dorman, 2021, Four-month rifapentine regimens with or without moxifloxacin for tuberculosis, The New England Journal of Medicine, 384, 1705, 10.1056/NEJMoa2033400 du Cros, 2021, Outcomes with a shorter multidrug-resistant tuberculosis regimen from Karakalpakstan, Uzbekistan, ERJ Open Research, 7, 00537, 10.1183/23120541.00537-2020 Fu, 2021, Insignificant difference in culture conversion between bedaquiline-containing and bedaquiline-free all-oral short regimens for multidrug-resistant tuberculosis, International Journal of Infectious Diseases: IJID: Official Publication of the International Society for Infectious Diseases, 111, 138, 10.1016/j.ijid.2021.08.055 Gao, 2021, Bedaquiline-containing regimens in patients with pulmonary multidrug-resistant tuberculosis in China: Focus on the safety, Infectious Diseases of Poverty, 10, 32, 10.1186/s40249-021-00819-2 Gils, 2022, Pretomanid for tuberculosis: A systematic review, Clinical Microbiology and Infection: The Official Publication of the European Society of Clinical Microbiology and Infectious Diseases, 28, 31, 10.1016/j.cmi.2021.08.007 Gómez-Calleja, 2022, Optic neuropathy by ethambutol in a patient with multiple sclerosis, Archivos de la Sociedad Española de Oftalmología, 97, 52, 10.1016/j.oftal.2020.12.009 Gupta, 2021, Levofloxacin based non-rifampicin anti-tuberculous therapy: An effective alternative in renal transplant recipients in resource limited setting, Nephrology (Carlton, Vic.), 26, 178, 10.1111/nep.13816 Haas, 2021, Higher completion rates with self-administered once-weekly isoniazid-rifapentine versus daily rifampin in adults with latent tuberculosis, Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America, 73, e3459, 10.1093/cid/ciaa1364 Hase, 2021, Pulmonary tuberculosis in older adults: Increased mortality related to tuberculosis within two months of treatment initiation, Drugs & Aging, 38, 807, 10.1007/s40266-021-00880-4 Herrera-Rodulfo, 2021, NAT2 polymorphisms associated with the development of hepatotoxicity after first-line tuberculosis treatment in Mexican patients: From genotype to molecular structure characterization, Clinica Chimica Acta; International Journal of Clinical Chemistry, 519, 153, 10.1016/j.cca.2021.04.017 Huang, 2021, Completion rate and safety of programmatic screening and treatment for latent tuberculosis infection in elderly patients with poorly controlled diabetic mellitus: A prospective multicenter study, Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America, 73, e1252, 10.1093/cid/ciab209 Huang, 2021, Impact of age on outcome of rifapentine-based weekly therapy for latent tuberculosis Infection, Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America, 73, e1064, 10.1093/cid/ciaa1741 Hwang, 2021, Outcomes of multidrug-resistant tuberculosis treated with bedaquiline or delamanid, Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America, 73, 1362, 10.1093/cid/ciab304 Jin, 2021, Severe cutaneous adverse reactions to anti-tuberculosis drugs in korean patients, Allergy, Asthma & Immunology Research, 13, 245, 10.4168/aair.2021.13.2.245 Kabengele, 2021, A peculiarly characterised case of isoniazid-induced pellagra-2 Ds and a C: A case report, The Pan African Medical Journal, 39, 73, 10.11604/pamj.2021.39.73.28072 Khoza-Shangase, 2021, Impact of drug-resistant tuberculosis treatment on hearing function in South African adults: Bedaquiline versus kanamycin, The South African Journal of Communication Disorders = Die Suid-Afrikaanse tydskrif vir Kommunikasieafwykings, 68, e1 Kim, 2021, Early bactericidal activity of delpazolid (LCB01–0371) in patients with pulmonary tuberculosis, Antimicrobial Agents and Chemotherapy Koirala, 2021, High success and low recurrence with shorter treatment regimen for multidrug-resistant TB in Nepal, Public Health Action, 11, 38, 10.5588/pha.21.0041 Kristensen, 2021, Ugeskrift for Laeger, 183 Kuwabara, 2021, Isoniazid-induced immune thrombocytopenia, Internal Medicine (Tokyo, Japan), 60, 3639, 10.2169/internalmedicine.6520-20 Lai, 2021, Publisher correction: Association between 9-month isoniazid prophylaxis of latent tuberculosis and severe hepatitis in patients treated with TNF inhibitors, Scientific Reports, 11, 20589, 10.1038/s41598-021-99382-x Laohapojanart, 2021, Efficacy and safety of combined isoniazid-rifampicin-pyrazinamide-levofloxacin dry powder inhaler in treatment of pulmonary tuberculosis: A randomized controlled trial, Pulmonary Pharmacology & Therapeutics, 70, 10.1016/j.pupt.2021.102056 Lee, 2021, Linezolid-induced black hairy tongue in a patient with multidrug-resistant tuberculosis: A case report, Science Progress, 104, 10.1177/00368504211042982 Li, 2021, Safety, efficacy, and serum concentration monitoring of bedaquiline in Chinese patients with multidrug-resistant tuberculosis, International Journal of Infectious Diseases: IJID: Official Publication of the International Society for Infectious Diseases, 110, 179, 10.1016/j.ijid.2021.07.038 Lin, 2021, Completion and adverse drug events of latent tuberculosis infection treatment in patients receiving dialysis: Predictors and impacts of different regimens in a prospective cohort study, Antimicrobial Agents and Chemotherapy, 65, 10.1128/AAC.02184-20 Liou, 2021, Short-course daily isoniazid and rifapentine for latent tuberculosis infection in people living with HIV who received coformulated bictegravir/emtricitabine/tenofovir alafenamide, Journal of the International AIDS Society, 24, 10.1002/jia2.25844 Liu, 2021, The association between cytochrome P450 polymorphisms and anti-tuberculosis drug-induced liver injury: A systematic review and meta-analysis, Annals of Palliative Medicine, 10, 6518, 10.21037/apm-21-1224 Malik, 2021, Risk factors for adverse events in household contacts prescribed preventive treatment for drug-resistant tuberculosis exposure, Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America, 72, 1709, 10.1093/cid/ciaa327 Martin, 2021, High rates of culture conversion and low loss to follow-up in MDR-TB patients managed at Regional Referral Hospitals in Uganda, BMC Infectious Diseases, 21, 1060, 10.1186/s12879-021-06743-y Matsumoto, 2021, Drastically progressive ethambutol-induced optic neuropathy after withdrawal of ethambutol: A case report and literature review, Internal Medicine (Tokyo, Japan), 60, 1785, 10.2169/internalmedicine.6178-20 Mbuh, 2021, Incidence of adverse drug events among patients on second line anti-tuberculosis regimen in the littoral region of cameroon, International Journal of Mycobacteriology, 10, 463, 10.4103/ijmy.ijmy_160_21 Misra, 2021, Standard versus sequential anti-tubercular treatment in patients with tuberculous meningitis: A randomized controlled trial, Transactions of the Royal Society of Tropical Medicine and Hygiene, 115, 94, 10.1093/trstmh/traa144 Mohammad, 2021, An unusual case of seizures in a 5-year-old Syrian female with abdominal tuberculosis: An isoniazid therapeutic dose side effect, Oxford Medical Case Reports, 2021, omaa126, 10.1093/omcr/omaa126 Mokhele, 2021, Treatment and pregnancy outcomes of pregnant women exposed to second-line anti-tuberculosis drugs in South Africa, BMC Pregnancy and Childbirth, 21, 453, 10.1186/s12884-021-03956-6 Nataprawira, 2021, Unusual recurrence of antituberculosis drug-induced hepatotoxicity in children: A case series, The American Journal of Case Reports, 22, 10.12659/AJCR.930828 Nataprawira, 2021, Two cases of pre-extensively drug resistant tuberculosis in children in Indonesia, Respiratory Medicine Case Reports, 34, 10.1016/j.rmcr.2021.101544 Nie, 2022, High-dose gatifloxacin-based shorter treatment regimens for MDR/RR-TB, International Journal of Infectious Diseases: IJID: Official Publication of the International Society for Infectious Diseases, 115, 142, 10.1016/j.ijid.2021.11.037 Onorato, 2021, Standard versus high dose of rifampicin in the treatment of pulmonary tuberculosis: A systematic review and meta-analysis, Clinical Microbiology and Infection : The Official Publication of the European Society of Clinical Microbiology and Infectious Diseases, 27, 830, 10.1016/j.cmi.2021.03.031 Pahadiya, 2021, Dapsone hypersensitivity syndrome with leukemoid reaction and severe thrombocytosis, Cureus, 13 Peck, 2021, Adverse events associated with weekly short course isoniazid and rifapentine therapy in pediatric patients with latent tuberculosis: A chart and literature review, Pediatric Pulmonology, 56, 2695, 10.1002/ppul.25456 Polat, 2021, Suicide attempt with isoniazid in adolescents receiving tuberculous prophylaxis: Three cases, Paediatrics and International Child Health, 41, 228, 10.1080/20469047.2021.1946651 Pratama, 2021, Hematological side effect analysis of linezolid in MDR-TB patients with individual therapy, Journal of Basic and Clinical Physiology and Pharmacology, 32, 777, 10.1515/jbcpp-2020-0468 Richardus, 2021, Leprosy post-exposure prophylaxis with single-dose rifampicin (LPEP): An international feasibility programme, The Lancet Global Health, 9, e81, 10.1016/S2214-109X(20)30396-X Ross, 2021, Isoniazid preventive therapy plus antiretroviral therapy for the prevention of tuberculosis: A systematic review and meta-analysis of individual participant data, The Lancet HIV, 8, e8, 10.1016/S2352-3018(20)30299-X Ruan, 2021, Efficacy and safety of weekly rifapentine and isoniazid for tuberculosis prevention in Chinese silicosis patients: A randomized controlled trial, Clinical Microbiology and Infection : The Official Publication of the European Society of Clinical Microbiology and Infectious Diseases, 27, 576, 10.1016/j.cmi.2020.06.008 Ruslami, 2022, Pharmacokinetics and safety/tolerability of isoniazid, rifampicin and pyrazinamide in children and adolescents treated for tuberculous meningitis, Archives of Disease in Childhood, 107, 70, 10.1136/archdischild-2020-321426 Sabur, 2021, Low-dose amikacin in the treatment of multidrug-resistant tuberculosis (MDR-TB), BMC Infectious Diseases, 21, 254, 10.1186/s12879-021-05947-6 Satapornpong, 2021, HLA-B*13:01 is a predictive marker of dapsone-induced severe cutaneous adverse reactions in Thai patients, Frontiers in Immunology, 12, 10.3389/fimmu.2021.661135 Sathi, 2021, Rifampicin-associated secondary minimal change disease presenting with nephrotic syndrome in a pulmonary tuberculosis patient, Case Reports in Nephrology, 2021, 5546942, 10.1155/2021/5546942 Scriba, 2021, Biomarker-guided tuberculosis preventive therapy (CORTIS): A randomised controlled trial, The Lancet Infectious Diseases, 21, 354, 10.1016/S1473-3099(20)30914-2 Semitala, 2021, Completion of isoniazid-rifapentine (3HP) for tuberculosis prevention among people living with HIV: Interim analysis of a hybrid type 3 effectiveness-implementation randomized trial, PLoS Medicine, 18, 10.1371/journal.pmed.1003875 Sharawat, 2021, Toddler with intermittent abnormal behavior: Is it isoniazid-induced psychosis?, Pediatric Emergency Care, 37, e60, 10.1097/PEC.0000000000001555 Shin, 2021, Hypersensitivity reactions to multiple anti-tuberculosis drugs, PLoS One, 16, 10.1371/journal.pone.0246291 Shrestha, 2021, Drug reaction with eosinophilia and systemic symptom (dress) following rifampicin treatment: A case report, Cureus, 13 Sidamo, 2021, Explorative analysis of treatment outcomes of levofloxacin- and moxifloxacin-based regimens and outcome predictors in Ethiopian MDR-TB patients: A prospective observational cohort study, Infection and Drug Resistance, 14, 5473, 10.2147/IDR.S342964 Silva, 2021, Experience with moxifloxacin for the treatment of latent tuberculosis infection in liver transplantation: A single-center prospective study, Liver Transplantation: Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society, 27, 913, 10.1002/lt.25961 Singh, 2021, The efficacy of bedaquiline versus kanamycin in multi-drug resistant tuberculosis: A systematic scoping review, Health SA = SA Gesondheid, 26, 1708 Solodovnikova, 2021, Effectiveness and safety of delamanid- or bedaquiline-containing regimens among children and adolescents with multidrug resistant or extensively drug resistant tuberculosis: A nationwide study from Belarus, 2015-19, Monaldi Archives for Chest Disease = Archivio Monaldi per le malattie del torace, 91 Souleymane, 2021, High rifampicin-resistant TB cure rates and prevention of severe ototoxicity after replacing the injectable by linezolid in early stage of hearing loss, The European Respiratory Journal, 57, 2002250, 10.1183/13993003.02250-2020 Sun, 2021, Moxifloxacin is a safe and effective candidate agent for tuberculosis treatment: A meta-analysis of randomized controlled trials, Annals of Palliative Medicine, 10, 2027, 10.21037/apm-20-2612 Sun, 2021, A highly effective and inexpensive standardized treatment of multidrug-resistant tuberculosis: A multicenter prospective study in China, BMC Infectious Diseases, 21, 834, 10.1186/s12879-021-06553-2 Surey, 2021, An open label, randomised controlled trial of rifapentine versus rifampicin based short course regimens for the treatment of latent tuberculosis in England: The HALT LTBI pilot study, BMC Infectious Diseases, 21, 90, 10.1186/s12879-021-05766-9 Tack, 2021, Safety and effectiveness of an all-oral, bedaquiline-based, shorter treatment regimen for rifampicin-resistant tuberculosis in high human immunodeficiency virus (HIV) burden rural South Africa: A retrospective cohort analysis, Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America, 73, e3563, 10.1093/cid/ciaa1894 Te Brake, 2021, Increased bactericidal activity but dose-limiting intolerability at 50mg·kg−1 rifampicin, The European Respiratory Journal, 58, 2000955, 10.1183/13993003.00955-2020 Tesfamariam, 2021, Secondary erythrocytosis following drugs used in rifampicin/multidrug-resistant tuberculosis: A retrospective cohort study, BMJ Open Respiratory Research, 8, 10.1136/bmjresp-2021-001064 Theron, 2021, Individual and composite adverse pregnancy outcomes in a randomized trial on isoniazid preventative therapy among women living with human immunodeficiency virus, Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America, 72, e784, 10.1093/cid/ciaa1482 Tolofoudie, 2021, Isoniazid preventive therapy in child household contacts of adults with active TB in Bamako, Mali, Public Health Action, 11, 191, 10.5588/pha.21.0061 Tortelly, 2021, Adverse effects of polychemotherapy for leprosy in 13 years of follow-up at a university hospital, Anais Brasileiros de Dermatologia, 96, 224, 10.1016/j.abd.2020.07.005 Tripathi, 2021, Dapsone-induced methaemoglobinaemia in leprosy: A close mimic of 'happy hypoxia' in the COVID-19 pandemic, Journal of the European Academy of Dermatology and Venereology: JEADV, 35, e568, 10.1111/jdv.17394 Trubnikov, 2021, Effectiveness and safety of a shorter treatment regimen in a setting with a high burden of multidrug-resistant tuberculosis, International Journal of Environmental Research and Public Health, 18, 4121, 10.3390/ijerph18084121 Tseng, 2021, Hepatotoxicity, efficacy and completion rate between 3 months of isoniazid plus rifapentine and 9 months of isoniazid in treating latent tuberculosis infection: A systematic review and meta-analysis, Journal of the Chinese Medical Association: JCMA, 84, 993, 10.1097/JCMA.0000000000000605 Tweed, 2021, A partially randomised trial of pretomanid, moxifloxacin and pyrazinamide for pulmonary TB, The International Journal of Tuberculosis and Lung Disease: The Official Journal of the International Union Against Tuberculosis and Lung Disease, 25, 305, 10.5588/ijtld.20.0513 Vučić, 2021, Diagnostic complexity of rifampicin-induced coagulopathy in a patient with spontaneous muscle bleeding: A case report, Medicine, 100, 10.1097/MD.0000000000026234 Wrohan, 2021, Ototoxicity among multidrug-resistant TB patients: A systematic review and meta-analysis, The International Journal of Tuberculosis and Lung Disease: The Official Journal of the International Union Against Tuberculosis and Lung Disease, 25, 23, 10.5588/ijtld.20.0217 Wu, 2022, Twenty-four-week interim outcomes of bedaquiline-containing regimens in treatment of adolescents with rifampicin-resistant tuberculosis: A retrospective cohort study in China, Journal of Paediatrics and Child Health, 58, 116, 10.1111/jpc.15672 Yanes-Lane, 2021, Tuberculosis preventive therapy for people living with HIV: A systematic review and network meta-analysis, PLoS Medicine, 18, 10.1371/journal.pmed.1003738 Yang, 2021, High rate of completion for weekly rifapentine plus isoniazid treatment in Chinese children with latent tuberculosis infection-A single center study, PLoS One, 16, 10.1371/journal.pone.0253159 Yang, 2021, High rate of completion for weekly rifapentine plus isoniazid treatment in Chinese children with latent tuberculosis infection-A single center study, PLoS One, 16, 10.1371/journal.pone.0253159 Yoo, 2021, A pilot study to investigate the utility of NAT2 genotype-guided isoniazid monotherapy regimens in NAT2 slow acetylators, Pharmacogenetics and Genomics, 31, 68, 10.1097/FPC.0000000000000423 Yuyaem, 2021, Ethambutol induced lichenoid drug eruption: A case report, Current Drug Safety, 16, 296, 10.2174/1574886315666201217095950 Zhu, 2021, Anti-tuberculosis drug-induced acute liver failure requiring transplantation in the second trimester of pregnancy: A case report, BMC Pregnancy and Childbirth, 21, 592, 10.1186/s12884-021-04065-0